within Pharmacolibrary.Drugs.C_CardiovascularSystem.C05C_CapillaryStabilizingAgents.C05CA04_Troxerutin;

model Troxerutin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.13,
    Cl = 2.3333333333333332e-05,
    adminDuration = 600,
    adminMass = 500 / 1000000,
    adminCount = 1,
    Vd = 0.0025,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0011333333333333334,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Troxerutin</td></tr><tr><td>ATC code:</td><td>C05CA04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>500</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>2.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Troxerutin is a flavonoid derivative with vasoprotective properties, used for the treatment of chronic venous insufficiency, hemorrhoids, and related vascular disorders. It is used in some countries, primarily in Europe and Asia, but is not approved by the US FDA.</p><h4>Pharmacokinetics</h4><p>PK parameters estimated based on available secondary literature and related flavonoid drugs, as no direct clinical pharmacokinetic studies in humans are published for troxerutin.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C05CA04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Troxerutin;
